These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 8584657)
21. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects. Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253 [TBL] [Abstract][Full Text] [Related]
22. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Schneider LS; Tariot PN; Goldstein B Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):750-6. PubMed ID: 7995017 [TBL] [Abstract][Full Text] [Related]
23. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Schneider LS; Olin JT; Pawluczyk S Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085 [TBL] [Abstract][Full Text] [Related]
24. Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients? Ames D; Ritchie C Int Psychogeriatr; 2007 Feb; 19(1):1-8. PubMed ID: 17310512 [No Abstract] [Full Text] [Related]
25. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. O' Neill C Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275 [TBL] [Abstract][Full Text] [Related]
26. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system. Knoll J J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730 [TBL] [Abstract][Full Text] [Related]
27. A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Campbell S; Trettien A; Kozan B Vet Ther; 2001; 2(1):24-39. PubMed ID: 19753696 [TBL] [Abstract][Full Text] [Related]
28. Vitamins in Alzheimer's Disease-Review of the Latest Reports. Mielech A; Puścion-Jakubik A; Markiewicz-Żukowska R; Socha K Nutrients; 2020 Nov; 12(11):. PubMed ID: 33187212 [TBL] [Abstract][Full Text] [Related]
29. The use of selegiline in Alzheimer's patients with behavior problems. Goad DL; Davis CM; Liem P; Fuselier CC; McCormack JR; Olsen KM J Clin Psychiatry; 1991 Aug; 52(8):342-5. PubMed ID: 1907964 [TBL] [Abstract][Full Text] [Related]
30. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Solfrizzi V; Panza F; Frisardi V; Seripa D; Logroscino G; Imbimbo BP; Pilotto A Expert Rev Neurother; 2011 May; 11(5):677-708. PubMed ID: 21539488 [TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology; 1998 Mar; 50(3):645-51. PubMed ID: 9521250 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Landsberg G Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):471-9. PubMed ID: 15795056 [TBL] [Abstract][Full Text] [Related]
33. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. Burke WJ; Roccaforte WH; Wengel SP; Bayer BL; Ranno AE; Willcockson NK J Am Geriatr Soc; 1993 Nov; 41(11):1219-25. PubMed ID: 8227897 [TBL] [Abstract][Full Text] [Related]
40. Alzheimer's disease in the zebrafish: where can we take it? Caramillo EM; Echevarria DJ Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):179-186. PubMed ID: 28177980 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]